---
title: "Gelteq publishes MD&A for six months ended Dec. 31, 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291337263.md"
description: "Gelteq published its MD&A for the six months ended Dec. 31, 2025. Key updates include completed human clinical trial planning with trials starting July 2026, a veterinary antiparasitic trial underway targeting an FDA application in late 2026, and a preclinical diabetes study. The company secured up to USD 3.5 million in debt financing and manufactured commercial products for a new East Asia customer, with deliveries expected in July 2026."
datetime: "2026-06-30T21:30:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291337263.md)
  - [en](https://longbridge.com/en/news/291337263.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291337263.md)
generator: "portal-rs"
---

# Gelteq publishes MD&A for six months ended Dec. 31, 2025

-   Gelteq published its MD&A for the six months ended Dec. 31, 2025, highlighting pipeline expansion across pharmaceutical, animal health, consumer health. \* Human clinical trial planning completed; trial expected to start next quarter beginning July 1, 2026, supporting a potential FDA pathway. \* Veterinary clinical trial started for an antiparasitic candidate; FDA application targeted for later in 2026. \* Preclinical diabetes study launched; development work underway to formulate peptides into stable oral products. \* Up to USD 3.5 million debt financing signed; commercial product manufactured for a new East Asia customer with delivery expected in July 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gelteq Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-073846), on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [GELS.US](https://longbridge.com/en/quote/GELS.US.md)

## Related News & Research

- [Alfresa unit signs commercialization deal for next-gen veterinary healthcare platform](https://longbridge.com/en/news/297593627.md)
- [Should Chewy’s Vet Clinic Push and Autoship Dependence Reshape Long-Term Cash Flows for CHWY Investors?](https://longbridge.com/en/news/297366123.md)
- [Vera Therapeutics management presents at Cantor Global Healthcare Conference 2026](https://longbridge.com/en/news/297644314.md)
- [12:15 ETPumpkin Enhances Pet Wellness Experience with Shift to Pumpkin Wellness Club from Preventive Essentials](https://longbridge.com/en/news/297212572.md)
- [Gaming and Leisure Properties declares Q3 2026 dividend of $0.82 per share](https://longbridge.com/en/news/297652371.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**